Studies on twins and families have suggested that susceptibility to Parkinson’s disease has a substantial genetic component. Now, an analysis of gene activity in different brain tissues has identified gene candidates that may be directly involved in causing the neurodegenerative disorder. The study, “A transcriptome-wide association study…
News
The Parkinson’s Foundation is launching a four-year, $30-million fundraising campaign to help advance Parkinson’s research and fund community services. The Reach Further campaign seeks to help accelerate research, increase patient access to healthcare, and enrich community services for those affected by Parkinson’s disease. “With the rate of…
TreeFrog Therapeutics has raised $75 million in financing to support the clinical development of its stem cell-derived cell therapies for Parkinson’s disease, the company said in a press release. The new financing round, which brings the total funding to date to $83 million, will allow the company to use…
The Michael J. Fox Foundation (MJFF) has released a new suite of free educational resources that focuses on so-called “off” periods when Parkinson’s disease symptoms reappear or worsen as medications wear off. These new resources, available at michaeljfox.org/off, offer patients and their families tips for managing “off” time,…
The antioxidant urate failed to slow Parkinson’s disease progression in newly diagnosed patients over two years, according to data from a Phase 3 clinical trial. “While our study did not rule out a protective effect of urate in Parkinson’s, it clearly showed that increasing urate did not slow disease…
High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…
The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…
A newly launched five-year, $3 million collaboration, called ENIGMA-PD, will investigate brain imaging, genetics, and clinical data in a global study of Parkinson’s disease. Research efforts in more than 20 countries will be combined in the new project, created by the University of Southern California’s Mark and Mary…
The use of non-steroidal anti-inflammatory drugs (NSAIDs) seems to have no effect on the incidence of Parkinson’s disease, according to a large retrospective Norwegian study. Researchers focused on the NSAIDs prescribed most in Norway: diclofenac, ibuprofen, and naproxen. In the study “NSAID use is not associated with Parkinson’s…
A potential Parkinson’s therapy based on a protein with an ability to protect neurons — called recombinant (lab-made) human cerebral dopamine neurotrophic factor (rhCDNF) — has been transformed into tiny nanoparticles that may allow for its use as a nasal spray, Herantis Pharma,…
Recent Posts
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s
- Low muscle mass is more common in early-stage Parkinson’s disease
- Guest Voice: What de facto parenting can teach us about Parkinson’s
- Parkinson’s advocates urge implementation of new federal plan